Skip to main content
PEPTARA LABS
Get Started

Semaglutide Research

Semaglutide Research: What the STEP 1 Trial Tested

Published by · Updated · How we research and check our pages

The short answer

Semaglutide research in the STEP 1 trial used one fixed plan, the same for every participant, given as an injection under the skin (Wilding et al., 2021). The trial followed 1961 adults with overweight or obesity for 68 weeks and reported about 15 percent average weight loss, against about 2.4 percent on placebo. This page covers what the trial studied and found. It does not repeat the dose figures.

This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.

What did the STEP 1 semaglutide trial study?

STEP 1 was a randomized, placebo-controlled trial of semaglutide in adults with overweight or obesity (Wilding et al., 2021). It enrolled 1961 adults and ran for 68 weeks. Everyone on the active arm followed the same fixed plan, given as a subcutaneous injection, so the dose was set by the protocol and not adjusted person by person. Its main measures were the change in body weight and the share of people who reached set weight-loss targets.

What side effects did the STEP 1 trial report?

Gastrointestinal side effects were the most commonly reported adverse events in the trial (Wilding et al., 2021). Reported events such as nausea, diarrhea, vomiting, and constipation were generally mild to moderate.

Is semaglutide studied the same way in weight and diabetes research?

No; the same molecule was studied under different plans depending on the research question (Wilding et al., 2021; Frias et al., 2021). STEP 1 studied body weight in adults with overweight or obesity. In the SURPASS-2 trial, people with type 2 diabetes were studied, and semaglutide was the active comparator against tirzepatide, under a different plan from STEP 1 (Frias et al., 2021). Because semaglutide is a GLP-1 receptor agonist studied across several programs, a single "the dose" figure does not exist. The trial and the population decide what was studied.

What weight change did the STEP 1 trial report?

STEP 1 reported a mean body-weight reduction of about 15 percent over 68 weeks in the semaglutide group, compared with about 2.4 percent for placebo (Wilding et al., 2021). Weight does not keep falling forever. In the two-year STEP 5 trial, weight measures appeared to plateau around week 60 (Garvey et al., 2022), and the body mounts metabolic adaptations, including adaptive thermogenesis, that resist further loss (Rosenbaum and Leibel, 2010).

What does research report about stopping semaglutide?

In the STEP 1 extension, participants regained about two-thirds of the weight they had lost within a year of stopping treatment (Wilding et al., 2022). This regain pattern is not unique to one compound: withdrawing tirzepatide in SURMOUNT-4 was also followed by weight regain (Aronne et al., 2024), which fits the metabolic adaptation described by Rosenbaum and Leibel (2010). The research points to these agents as ongoing rather than short-course interventions.

How do the semaglutide and tirzepatide trials compare?

They are different compounds with different potencies, and their reported outcomes differ (Wilding et al., 2021; Jastreboff et al., 2022). The grid below sets the trials and their results side by side.

TrialCompoundReported outcomeSource
STEP 1SemaglutideAbout 15 percent mean weight loss over 68 weeksWilding et al., 2021
SURPASS-2Semaglutide (comparator)Active comparator vs tirzepatide in type 2 diabetesFrias et al., 2021
SURMOUNT-1TirzepatideUp to about 22.5 percent weight loss in the highest dose groupJastreboff et al., 2022

Each molecule has its own potency, so an amount of one tells you nothing about the other. SURMOUNT-1 also tested three dose groups of tirzepatide against placebo (Jastreboff et al., 2022), while STEP 1 used one plan for all (Wilding et al., 2021), so the two trials were not built to be compared head to head.

Is a trial plan the same as a prescription?

No. The STEP 1 dose was chosen for 1961 trial volunteers who were screened, checked and followed by study staff for 68 weeks, which is why this page leaves the number out. Peptara Labs sells research material for lab use only, not a treatment. Semaglutide is a GLP-1 receptor agonist, and dose selection depends on individual medical history, goals, and monitoring. Any decision about whether, what, or how much to take belongs with a qualified clinician.

Related reading

To go deeper on the science and the comparisons behind these trials:

Semaglutide Research: FAQ

Does semaglutide weight loss keep going indefinitely?

Not necessarily; in the STEP 5 trial weight measures appeared to plateau around week 60 (Garvey et al., 2022), and the body mounts adaptations that resist further loss (Rosenbaum and Leibel, 2010).

What were the most common side effects in STEP 1?

Stomach and gut problems such as nausea, diarrhea, vomiting and constipation were the most commonly reported adverse events in STEP 1, and most were mild to moderate (Wilding et al., 2021).

Can the STEP 1 trial tell me what dose to use?

A research page cannot answer that. Dose selection is individual and belongs with a qualified clinician. This page reports trial data only.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002. doi:10.1056/NEJMoa2032183. PMID 33567185.
  2. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725. PMID 35441470.
  3. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4.
  4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515. doi:10.1056/NEJMoa2107519.
  5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. doi:10.1056/NEJMoa2206038. PMID 35658024.
  6. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945.
  7. Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes (Lond). 2010;34(Suppl 1):S47-S55. doi:10.1038/ijo.2010.184. PMID 20935667.

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.

Chat with us